% IMPORTANT: The following is UTF-8 encoded. This means that in the presence % of non-ASCII characters, it will not work with BibTeX 0.99 or older. % Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or % “biber”. @INBOOK{Drzezga:911484, author = {Drzezga, Alexander and Bischof, Gérard and Giehl, Kathrin and Eimeren, Thilo van}, title = {{PET} and {SPECT} {I}maging of {N}eurodegenerative {D}iseases}, address = {Amsterdam}, publisher = {Elsevier}, reportid = {FZJ-2022-04753}, pages = {1309-1334}, year = {2021}, note = {}, comment = {Molecular Imaging: Principles and Practice}, booktitle = {Molecular Imaging: Principles and Practice}, abstract = {Today, a number of complementary molecular imaging methods are at our disposal, which can make a relevant contribution to early diagnosis, differential diagnosis, disease monitoring, and follow-up of neurodegenerative diseases. This includes long-established FDG-PET which provides valuable information on location and extent of pathology and has demonstrated great value for early diagnosis, short-term prognosis, and for differential diagnosis of various disorders on the basis of the endophenotype of disease. Imaging of the dopaminergic system has proven value in the workup of movement disorders. More recently introduced, amyloid-PET for the first time allows in vivo diagnostic assessment of a molecular neuropathology, most valuable for verification or exclusion of Alzheimer disease (AD), independent of the symptomatic appearance. Finally, new tracers for tau-PET imaging may allow the assessment of location, extent, and specific type of pathology, which may hold great value for early and differential diagnosis of neurodegeneration in the future.}, cin = {INM-2}, cid = {I:(DE-Juel1)INM-2-20090406}, pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525) / 5253 - Neuroimaging (POF4-525)}, pid = {G:(DE-HGF)POF4-5252 / G:(DE-HGF)POF4-5253}, typ = {PUB:(DE-HGF)7}, url = {https://juser.fz-juelich.de/record/911484}, }